| SupremeCmdr Oct 19 | In people with coronary artery disease, rosuvastatin and atorvastatin showed comparable efficacy in terms of a composite of all cause death, myocardial infarction, stroke, or any coronary revascularisation within three years Rosuvastatin was associated with greater efficacy in reducing LDL cholesterol levels, but it incurred a higher risk of new onset diabetes mellitus requiring antidiabetics and cataract surgery than atorvastatin Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial - BMJ 2023;383:e075837 -- https://doi.org/10.1136/bmj-2023-075837 | | | | You can also reply to this email to leave a comment. | | | | |
No comments:
Post a Comment